Genetic deletion of Id2 impairs CD8+ T cell-mediated immune responses, reduces stem-like CD8+ T cell maintenance (43), diminishes anti-PD-1 efficacy, and increases tumor susceptibility. This evidence concerns the gene CD8A and neoplasm.